Breaking News Instant updates and real-time market news.

CNC

Centene

$144.81

1.61 (1.12%)

, WCG

WellCare

$320.50

-0.22 (-0.07%)

11:52
09/29/18
09/29
11:52
09/29/18
11:52

Midterms could boost some healthcare stocks, Barron's says

Potential electoral results could favor the outlook for policies beneficial to a wide range of hospital, pharmaceutical, and other healthcare-related companies, Lauren Rublin writes in this week's edition of Barron's. Policy experts favor Centene (CNC), WellCare Health (WCG), Molina Healthcare (MOH), HCA Healthcare (HCA), Tenet (THC), Encompass Health (EHC), Becton Dickinson (BDX), Cerner (CERN), Dentsply Sirona (XRAY) and Teladoc Health (TDOC) as beneficiaries of Medicaid expansion under the Affordable Care Act, the reported noted, adding that is especially likely if Democrats win more state elections. Reference Link

CNC

Centene

$144.81

1.61 (1.12%)

WCG

WellCare

$320.50

-0.22 (-0.07%)

MOH

Molina Healthcare

$148.73

1.01 (0.68%)

HCA

HCA Healthcare

$139.09

0.75 (0.54%)

THC

Tenet

$28.45

0.1 (0.35%)

EHC

Encompass Health

$78.01

1.33 (1.73%)

BDX

Becton Dickinson

$260.90

1.04 (0.40%)

CERN

Cerner

$64.42

0.21 (0.33%)

XRAY

Dentsply Sirona

$37.74

-0.22 (-0.58%)

TDOC

Teladoc

$86.35

3.85 (4.67%)

  • 03

    Oct

  • 11

    Oct

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

  • 11

    Dec

  • 14

    Dec

CNC Centene
$144.81

1.61 (1.12%)

09/19/18
MUFG
09/19/18
INITIATION
Target $170
MUFG
Overweight
Centene initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started Centene with an Overweight rating and $170 price target. The analyst sees an attractive risk/reward profile given the stock's discount to peers. He believes Centene's "significant" Medicaid and Medicare growth opportunities make the discount unwarranted.
07/25/18
FBCO
07/25/18
NO CHANGE
Target $134
FBCO
Neutral
Centene price target raised to $134 from $125 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Centene to $134 from $125, while reiterating a Neutral rating on the shares. The analyst believes there was more noise than expected for a Q2 on the heels of an Investor Day.
09/04/18
FBCO
09/04/18
NO CHANGE
Target $152
FBCO
Neutral
Centene price target raised to $152 from $134 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Centene to $152 from $134 after surveying 737 health benefit managers across the country to gain insight into market perceptions regarding national health insurers, cost trends, premium expectations, and employer priorities heading into 2019. The analyst notes that the survey bodes well for his MCOs coverage. He reiterates a Neutral rating on the shares.
09/28/18
OPCO
09/28/18
NO CHANGE
Target $89
OPCO
Outperform
Teladoc price target raised to $89 from $68 at Oppenheimer
Oppenheimer analyst Mohan Naidu reiterated an Outperform rating on Teledoc and raised his price target to $89 from $68 following the company's analyst day, which highlighted its new deal flow, including relationships with Centene (CNC) and Exxon (XOM), and a very strong pipeline. The recent CMS telehealth proposal makes Medicare a 2020 tailwind, Naidu tells investors in a research note, and says he has gained confidence that Teladoc's competitive barriers include its broad platform and its network of physicians that quickly matches supply and demand.
WCG WellCare
$320.50

-0.22 (-0.07%)

08/31/18
ARGS
08/31/18
NO CHANGE
Target $360
ARGS
Buy
WellCare price target raised to $360 from $265 at Argus
Argus analyst David Toung raised his price target on WellCare to $360 and kept his Buy rating, saying the company's acquisition of Meridian is a reflection of its "expansion mode". The analyst also raised his FY19 EPS view to $12.60 from $12.00, stating that WellCare's growth opportunities from its M&A strategy justifies its premium valuation of 24.1-times his expected forward earnings - above the peer average of 19.0-times. Toung maintains that WellCare will continue to grow through acquisitions, increased Medicare Advantage coverage, and new contract awards.
09/14/18
BMOC
09/14/18
NO CHANGE
Target $345
BMOC
Outperform
WellCare price target raised to $345 from $320 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on WellCare to $345 to reflect the potential organic upside for FY18 EPS as well as the accretion from its Meridian acquisition in FY19-FY20. The analyst maintains his view of the deal as a "very good strategic fit" to match WellCare's expansion objectives, adding that its recent Medicaid wins in Illinois and Michigan also gives WellCare a leading market position in 6 states. Borsch kept his his Outperform rating on the shares, forecasting its core business growth rate to be sustained at over 15%.
09/17/18
CANT
09/17/18
NO CHANGE
Target $330
CANT
Overweight
WellCare price target raised to $330 from $292 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for WellCare Health Plans to $330 after incorporating the recently closed acquisition of Meridian into his 2018 estimates. The analyst now assumes high single-digit revenue growth and thinks the company's margin expansion "is quite achievable" for the near-to-mid-term. He keeps an Overweight rating on WellCare.
08/01/18
RHCO
08/01/18
NO CHANGE
Target $315
RHCO
Buy
WellCare price target raised to $315 from $295 at SunTrust
SunTrust analyst David MacDonald raised his price target on WellCare to $315 and kept his Buy rating, saying the company's Q2 earnings beat was driven by "strong core trends". The analyst also cites "superb" visibility around the company's "impressive" win rates and its large number of members in states with leading market share. MacDonald adds that Wellcare's Medicare Advantage trends are solid, and that the company is "superbly positioned" to accelerate trends in 2019.
MOH Molina Healthcare
$148.73

1.01 (0.68%)

08/02/18
RHCO
08/02/18
NO CHANGE
Target $140
RHCO
Buy
Molina Healthcare price target raised to $140 from $120 at SunTrust
SunTrust analyst David MacDonald raised his price target on Molina Healthcare to $140 and kept his Buy rating after its "blowout" Q2 results driven by "stronger premium revenue, sequential MCR improvement, solid G&A expense control, and marketplace outperformance." The analyst also cites the company's improving capital structure and "meaningful" margin expansion, raising his FY18 EPS view to $7.52 from $4.58.
08/02/18
WELS
08/02/18
NO CHANGE
Target $120
WELS
Market Perform
Molina Healthcare price target raised to $120 from $92 at Wells Fargo
Wells Fargo raised its price target for Molina Healthcare to $120 from $92 after the company reported a notably better than expected Q2 driving an improved outlook. The firm reiterates a Market Perform rating on the shares.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $165
PIPR
Overweight
Molina Healthcare price target raised to $165 from $134 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $165 and keeps an Overweight rating on the shares. Puerto Rico finalized the auto assignment process for the $2.2B contract starting November 1, and while Molina is is not confirming the impact, the analyst believes it could be a $150M revenue headwind for the company. Nonetheless, James feels confident in the company's Q3 results. She believes much of the turnaround success demonstrated in Q2 "will continue to have lasting impacts such as network design and contracting and admin. efficiency."
08/02/18
PIPR
08/02/18
NO CHANGE
Target $134
PIPR
Overweight
Molina Healthcare price target raised to $134 from $106 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Molina Healthcare to $134 saying the company's turnaround is running ahead of schedule. Management could raise 2019 guidance at the next investor day driven by faster margin recovery and potentially capital deployment, James tells investors in a research note following Molina's Q2 results. The analyst reiterates an Overweight rating on the shares.
HCA HCA Healthcare
$139.09

0.75 (0.54%)

09/06/18
ARGS
09/06/18
NO CHANGE
Target $150
ARGS
Buy
HCA Healthcare price target raised to $150 from $116 at Argus
Argus analyst Jasper Hellweg raised his price target on HCA Healthcare to $150 and kept his Buy rating, saying the company's recent acquisition of Mission Heath in North Carolina strengthens its regional presence. The analyst also cites the managements expectations of healthcare services demand rising 2.0-2.5% annually on "population growth, strong economic conditions, higher medical utilization, and an increase in the number of patients with chronic conditions." Hellweg raises his FY18 EPS view on HCA Healthcare to $9.24 from $8.74, adding that its valuation is "attractive" at 14.4-times expected FY18 earnings vs. 17.5-times peer group average.
09/10/18
RBCM
09/10/18
NO CHANGE
Target $150
RBCM
Outperform
HCA Healthcare price target raised to $150 from $130 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on HCA Healthcare to $150 and kept his Outperform rating, citing the financial contribution from "several pending transitions" that are yet to close. The analyst highlights the $1.5B deal to acquire Mission Health in North Carolina and North Cypress in Houston, stating that these will add to the company's anticipated tailwinds in 2019. Morgan is also positive on the "improved performance" from HCA Heathcare's other Houston-area hospitals that were acquired from Tenet last year.
09/20/18
BARD
09/20/18
NO CHANGE
Target $150
BARD
Outperform
HCA Healthcare price target raised to $150 from $130 at Baird
Baird analyst Matthew Gillmor raised his price target on HCA Healthcare to $150 from $130 to reflect positive management commentary at an investor conference and the pending Mission Health acquisition. Gillmor reiterated his Outperform rating and called HCA Healthcare his preferred hospital idea.
09/20/18
JEFF
09/20/18
NO CHANGE
Target $155
JEFF
Buy
HCA Healthcare price target raised to $155 from $135 at Jefferies
Jefferies analyst Brian Tanquilut raised his price target for HCA Healthcare to $155 saying the stock "still has room to run" despite the year-to-date rally. HCA is well positioned to deliver organic revenue and EBITDA growth acceleration in the next few years, as it benefits from economic/population growth in its markets, strategic investments and selective acquisitions, Tanquilut tells investors in a research note. Further, the analyst believes "easy" Q3 comps and the tailwind from an upcoming Medicare rate bump "should provide incremental stock momentum." He keeps a Buy rating on the shares.
THC Tenet
$28.45

0.1 (0.35%)

08/08/18
MZHO
08/08/18
NO CHANGE
Target $36
MZHO
Buy
Tenet post-earnings selloff seems overdone, says Mizuho
Mizuho analyst Ann Hynes believes the post-earnings selloff yesterday in shares of Tenet Healthcare seems overdone. The Q2 earnings report shows Tenet has initiatives underway that should improve its earnings, margin and cash flow profile, Hynes tells investors in a research note. The analyst raised her price target for the shares to $36 from $35 and keeps a Buy rating on Tenet.
08/14/18
LEHM
08/14/18
INITIATION
Target $35
LEHM
Equal Weight
Tenet initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Tenet Healthcare with an Equal Weight rating and $35 price target.
07/23/18
SBSH
07/23/18
NO CHANGE
Target $44
SBSH
Buy
Tenet price target raised to $44 from $37 at Citi
Citi analyst Ralph Giacobbe raised his price target for Tenet Healthcare to $44 saying he sees additional upside in the stock despite the 140% rally year-to-date. There is an underappreciation for additional upside within the hospital segment specifically around margin improvement, Giacobbe tells investors in a research note partially titled "Debunking the Rationale for Lower Margins." He keeps a Buy rating on Tenet.
08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
EHC Encompass Health
$78.01

1.33 (1.73%)

07/26/18
07/26/18
UPGRADE
Target $87

Overweight
Encompass Health upgraded to Overweight on top-line growth potential at Piper Jaffray
As previously reported, Piper Jaffray analyst Sarah James upgraded Encompass Health to Overweight from Neutral and raised her price target on the stock to $87 from $68 following her deep dive into top-line growth opportunities and rate risk. Noting that Encompass Health is her top pick within the facility space, the analyst says its strong balance sheet gives it the opportunity to meaningfully move top-line growth through M&A. Further, James sees potential for the HH segment to increase 43% through strategically placed assets and higher collaboration rates.
04/30/18
CHLM
04/30/18
NO CHANGE
Target $71
CHLM
Buy
Encompass Health price target raised to $71 from $63 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Encompass Health to $71 from $63 following a Q1 beat and raise. The analyst reiterates a Buy rating on the shares.
04/30/18
RBCM
04/30/18
NO CHANGE
Target $69
RBCM
Outperform
Encompass Health price target raised to $69 from $64 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on Encompass Health to $69, saying the company's Q1 marked "another strong quarter with continued topline growth on impressive organic volumes". Morgan also notes that the company's operating leverage is "impressive" while its labor management is "effective", adding that Encompass Health is off to a great start on its rebranding efforts. The analyst keeps his Outperform rating.
07/26/18
PIPR
07/26/18
UPGRADE
PIPR
Overweight
Encompass Health upgraded to Overweight from Neutral at Piper Jaffray
BDX Becton Dickinson
$260.90

1.04 (0.40%)

06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
WELS
09/06/18
NO CHANGE
Target $290
WELS
Outperform
Becton Dickinson price target raised to $290 form $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Becton Dickinson to $290 from $275 based on a blend of P/E and EV/EBITDA multiples to reflect increased peer group valuation. After hosting the company's management, the analyst believes that it has a good line of sight into key businesses and is confident in delivering 7% top-line growth in Q4. Biegelsen reiterates an Outperform rating on the shares.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
06/21/18
JPMS
06/21/18
UPGRADE
Target $275
JPMS
Overweight
Becton Dickinson upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Robbie Marcus upgraded Becton Dickinson to Overweight and raised his price target for the shares to $275 from $250. The analyst sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. With sustainable 5% organic sales growth, a minimum of low-double-digit earnings growth "arguably a given for the foreseeable future," and sustainable 90% free cash flow conversion, Becton deserves a premium multiple even after factoring in its leverage, Marcus tells investors in a research note.
CERN Cerner
$64.42

0.21 (0.33%)

08/16/18
CANT
08/16/18
NO CHANGE
CANT
Overweight
Cantor Fitzgerald backs 'positive' view of healthcare IT segment
Cantor Fitzgerald Steven Halper tells investors in a research note that he is maintaining a positive investment view of the healthcare IT segment, and believes demand for products and services in the sector will continue to drive long-term growth. Specifically, he continues to rate Cerner (CERN) and Evolent Health (EVH) Overweight, as both are "nicely" leveraged to population health, with Evolent mostly a pure play in the segment. Within managed care, Halper believes Overweight-rated UnitedHealth (UNH) remains well-positioned with its Optum segment.
08/13/18
OPCO
08/13/18
NO CHANGE
OPCO
CMS guidelines 'a strong tailwind' for Evolent Health, says Oppenheimer
Oppenheimer analyst Mohan Naidu notes that CMS's new risk-based model rules confirm his expectation of a much more expedited and aggressive move to push providers toward higher double-sided risk models. The draft lays a path for ACOs to 2-sided profit/loss-sharing models starting with 25% profit-only sharing to 75% profit/loss-sharing, he adds. The analyst believes these rules will force providers to seek solutions and services that help organizations manage risk and perform better in risk contracts. Naidu thinks the biggest beneficiary of these movements is Evolent Health (EVH), and given Cerner's (CERN) recent investment into Lumeris and their position in hospitals, it is likely to benefit as well. Also, the draft highlights the use of telehealth and medication therapy management, further validating his bullishness on Teladoc (TDOC) and Tabula Rasa HealthCare (TRHC).
09/13/18
LEHM
09/13/18
INITIATION
Target $70
LEHM
Equal Weight
Cerner initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Cerner with an Equal Weight rating and $70 price target.
09/13/18
LEHM
09/13/18
INITIATION
Target $370
LEHM
Overweight
Barclays sees favorable Medicare Advantage outlook, starts Humana at Overweight
Barclays analyst Steve Valiquette initiated coverage of Humana (HUM) with an Overweight rating and $370 price target. The fundamental Medicare Advantage outlook is the strongest it has been since pre-Affordable Care Act levels "thanks to a number of industry tailwinds brought about by the Republican administration," Valiquette tells investors in a research note. These include higher Medicare reimbursement, corporate tax reform, and 2019 health insurance fund suspension, the analyst says. He believes Humana will be able to deliver on its low-to-mid-teens annual adjusted earnings target through at least 2021. Valiquette this morning also initiated coverage of Cerner with an Equal Weight rating and $70 price target. The company's 7%-12% revenue growth outlook relies on the ramp-up of newer products, the analyst contends.
XRAY Dentsply Sirona
$37.74

-0.22 (-0.58%)

08/09/18
BRRR
08/09/18
DOWNGRADE
BRRR
Market Perform
Dentsply Sirona downgraded to Market Perform from Outperform at Barrington
08/09/18
BRRR
08/09/18
DOWNGRADE
BRRR
Market Perform
Dentsply Sirona downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Dentsply Sirona to Market Perform saying the company's reduced 2018 guidance is "highly disappointing." The analyst sees "massive uncertainty" surrounding the company's business beyond this year.
08/31/18
HCWC
08/31/18
NO CHANGE
Target $40
HCWC
Neutral
Dentsply Sirona may lower earnings guidance further, says H.C. Wainwright
Lower dental segment operating margins at Patterson Companies (PDCO) may hinder earnings growth at Dentsply Sirona (XRAY), H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. Patterson's dental segment in its fiscal Q1 results showed an internal sales decline of 2.7% year-over-year, following a decline of 10.5% in the previous quarter, Selvaraju points out. The analyst would not be surprised if Dentsply lowers its earnings guidance further in the coming quarter. He reiterates a Neutral rating on the shares with a $40 price target.
08/08/18
08/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Aramark (ARMK) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying the shares rallied following its results, which helped balance the risk/reward. 2. Hostess Brands (TWNK) downgraded to Sector Perform from Outperform at RBC Capital and to Hold from Buy at SunTrust. 3. Spark Therapeutics (ONCE) downgraded to Market Perform from Outperform at BMO Capital with analyst Matthew Luchini saying he believes that the company's latest SPK-8011 hemA data falls short of expectations, with totality of the data suggesting a "less competitive profile versus valrox" and reducing his confidence in the program. 4. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at Raymond James with analyst Elliot WIlbur saying pipeline optionality remains high and is heavily discounted by valuation, and sees no "rational valuation framework" to support further upside. 5. Dentsply Sirona (XRAY) downgraded to Equal Weight from Overweight at Stephens and to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TDOC Teladoc
$86.35

3.85 (4.67%)

09/28/18
ADAM
09/28/18
NO CHANGE
Target $94
ADAM
Buy
Teladoc price target raised to $94 from $86 at Canaccord
Canaccord analyst Richard Close raised his price target on Teladoc to $94 from $86 following its "impressive" investor day. The analyst noted the company raised its guidance and shed some light on the international opportunity. He believes the company has strong sustainable momentum with global opportunities and is just beginning to scratch the surface. Close reiterated his Buy rating on Teladoc shares.
09/28/18
CANT
09/28/18
NO CHANGE
Target $83
CANT
Neutral
Teladoc price target raised to $83 from $52 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Teladoc to $83 saying the company at its investor meeting provided a bullish overview of its long-term growth potential. The analyst, however, reiterates a Neutral rating on the shares. He believes the stock at current valuation levels reflects his revised long-term growth assumptions.
09/28/18
SBSH
09/28/18
NO CHANGE
Target $95
SBSH
Buy
Teladoc price target raised to $95 from $88 at Citi
Citi analyst Stephanie Demko raised her price target for Teladoc to $95 after the company held its second annual investor day yesterday. Management's tone was positive on the macro environment, new wins and momentum as the business gains scale, Demko tells investors in a research note. She left the meeting "incrementally more positive" on the company's growth sustainability through 2020 and beyond. The analyst reiterates a Buy rating on Teladoc.

TODAY'S FREE FLY STORIES

CYTX

Cytori Therapeutics

$0.34

-0.0064 (-1.87%)

07:21
11/15/18
11/15
07:21
11/15/18
07:21
Recommendations
Cytori Therapeutics analyst commentary  »

Cytori Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$157.15

-1 (-0.63%)

07:20
11/15/18
11/15
07:20
11/15/18
07:20
Conference/Events
Air Products management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PCG

PG&E

$25.66

-7.04 (-21.53%)

07:19
11/15/18
11/15
07:19
11/15/18
07:19
Downgrade
PG&E rating change  »

PG&E downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.55

0.01 (0.10%)

, VLKAY

Volkswagen

$0.00

(0.00%)

07:18
11/15/18
11/15
07:18
11/15/18
07:18
Periodicals
Ford CEO open to autonomous vehicles investors but cautious on VW, Reuters says »

Ford Motor (F) CEO Jim…

F

Ford

$9.55

0.01 (0.10%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

KBH

KB Home

$20.80

-0.135 (-0.64%)

07:17
11/15/18
11/15
07:17
11/15/18
07:17
Recommendations
KB Home analyst commentary  »

KB Home price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRO

Frontline

$5.93

-0.1 (-1.66%)

07:17
11/15/18
11/15
07:17
11/15/18
07:17
Upgrade
Frontline rating change  »

Frontline upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPTN

SpartanNash

$16.99

-0.44 (-2.52%)

07:17
11/15/18
11/15
07:17
11/15/18
07:17
Upgrade
SpartanNash rating change  »

SpartanNash upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HGV

Hilton Grand Vacations

$28.27

0.48 (1.73%)

07:16
11/15/18
11/15
07:16
11/15/18
07:16
Upgrade
Hilton Grand Vacations rating change  »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

OAS

Oasis Petroleum

$8.28

-0.04 (-0.48%)

07:16
11/15/18
11/15
07:16
11/15/18
07:16
Upgrade
Oasis Petroleum rating change  »

Oasis Petroleum upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

CNST

Constellation Pharmaceuticals

$5.83

0.025 (0.43%)

07:16
11/15/18
11/15
07:16
11/15/18
07:16
Hot Stocks
Constellation Pharmaceuticals to present data on EZH2 program at conference »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

APRN

Blue Apron

$1.17

-0.055 (-4.51%)

07:15
11/15/18
11/15
07:15
11/15/18
07:15
Recommendations
Blue Apron analyst commentary  »

Blue Apron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

BECN

Beacon Roofing

$28.07

0.81 (2.97%)

07:14
11/15/18
11/15
07:14
11/15/18
07:14
Recommendations
Beacon Roofing analyst commentary  »

Beacon Roofing price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 13

    Dec

WEX

Wex

$157.62

-4.01 (-2.48%)

07:14
11/15/18
11/15
07:14
11/15/18
07:14
Recommendations
Wex analyst commentary  »

JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$22.79

-1.16 (-4.84%)

07:14
11/15/18
11/15
07:14
11/15/18
07:14
Hot Stocks
uniQure announces data from dose-confirmation study of AMT-061 »

uniQure announced initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$101.58

-1.37 (-1.33%)

07:14
11/15/18
11/15
07:14
11/15/18
07:14
Hot Stocks
Walmart CEO says continues to see 'strong' comp store sales »

President and CEO Doug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

F

Ford

$9.55

0.01 (0.10%)

07:11
11/15/18
11/15
07:11
11/15/18
07:11
Periodicals
Ford plans ride-sharing service with autonomous vehicles by 2021, CNBC reports »

Ford has been road…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

FOCS

Focus Financial Partners

$30.43

-1.54 (-4.82%)

07:11
11/15/18
11/15
07:11
11/15/18
07:11
Recommendations
Focus Financial Partners analyst commentary  »

Focus Financial Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$26.91

-0.74 (-2.68%)

07:10
11/15/18
11/15
07:10
11/15/18
07:10
Hot Stocks
Synchrony reports October net charge-off rate 4.85% vs. 4.50% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SR

Spire

$76.03

-0.36 (-0.47%)

07:10
11/15/18
11/15
07:10
11/15/18
07:10
Earnings
Spire sees FY19 economic EPS $3.70-$3.80, consensus $3.68 »

FY19 CapEx are expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

BGNE

BeiGene

$124.56

9.79 (8.53%)

07:10
11/15/18
11/15
07:10
11/15/18
07:10
Hot Stocks
BeiGene receives priority review from China's NMPA for zanubrutinib »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 16

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

SR

Spire

$76.03

-0.36 (-0.47%)

07:09
11/15/18
11/15
07:09
11/15/18
07:09
Earnings
Spire reports Q4 EPS (52c), consensus (59c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

JPM

JPMorgan

$107.36

-2.23 (-2.03%)

07:08
11/15/18
11/15
07:08
11/15/18
07:08
Hot Stocks
JPMorgan reports October net credit losses 2.19% vs. 2.22% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WMT

Walmart

$101.58

-1.37 (-1.33%)

07:07
11/15/18
11/15
07:07
11/15/18
07:07
Hot Stocks
Walmart raises FY19 Walmart U.S. comp sales tp up at least 3% »

Walmart now sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

MDR

McDermott

$7.89

0.28 (3.68%)

, BHGE

Baker Hughes

$22.97

-0.65 (-2.75%)

07:07
11/15/18
11/15
07:07
11/15/18
07:07
Hot Stocks
McDermott awarded engineering services contract by Talos Energy for Zama field »

McDermott (MDR) announced…

MDR

McDermott

$7.89

0.28 (3.68%)

BHGE

Baker Hughes

$22.97

-0.65 (-2.75%)

TALO

Talos Energy

$21.56

-0.12 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 29

    Nov

  • 14

    Nov

DVMT

Dell Technologies

$105.75

4.13 (4.06%)

07:06
11/15/18
11/15
07:06
11/15/18
07:06
Hot Stocks
Dell Technologies sees closing Class V transaction by end of 2018 »

Dell Technologies today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.